DelveInsight's "Relapsed/Refractory Multiple Myeloma Pipeline Insight, 2025" report delivers extensive analysis on over 55 companies and more than 60 pipeline drugs in the Relapsed/Refractory Multiple Myeloma treatment arena. It includes thorough profiles of Relapsing Refractory Multiple Myeloma pipeline drugs, encompassing clinical and nonclinical development stages. Additionally, it evaluates Relapsing Refractory Multiple Myeloma pipeline therapeutics by product category, development phase, administration method, and molecular structure. It also points out discontinued pipeline products in this domain.

Stay ahead with the latest insights! Obtain DelveInsight's thorough Relapsing Refractory Multiple Myeloma Pipeline Report to explore emerging treatments, key Companies, and future treatment landscapes @ Relapsing Refractory Multiple Myeloma Pipeline Outlook Report

Key Takeaways from the Relapsing Refractory Multiple Myeloma Pipeline Report

• On October 24, 2025, BeiGene disclosed a trial to evaluate the safety, tolerability, and effectiveness of sonrotoclax as a standalone treatment and in various combinations in patients with relapsed/refractory (R/R) multiple myeloma (MM) and chromosomal translocation t(11;14). The study examines sonrotoclax alone and combined with dexamethasone and other agents, such as carfilzomib, daratumumab, and pomalidomide.

• On October 20, 2025, Juno Therapeutics Inc. conducted a trial to compare the effectiveness and safety of arlo-cel (BMS-986393) against standard regimens in adult participants with Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma.

• DelveInsight's Relapsing Refractory Multiple Myeloma pipeline report illustrates a vibrant arena with over 55 active contributors developing more than 60 pipeline treatments for Relapsing Refractory Multiple Myeloma care.

• The prominent Relapsing Refractory Multiple Myeloma Companies include Bristol-Myers Squibb, I-MAB Biopharma, Pfizer, Arcellx, Gilead Sciences, Novartis, Array Biopharma, Hrain Biotechnology Co., Ltd., Cartesian Therapeutics, Xencor, Takeda, Sorrento Therapeutics, Heidelberg Pharma AG, Ichnos Sciences, Allogene Therapeutics, Harpoon Therapeutics, Cellectis, Poseida Therapeutics, Regeneron Pharmaceuticals, ONK Therapeutics, TeneoOne, iTeos Therapeutics, Oricell Therapeutics, Anaveon AG, Luminary Therapeutics, Seagen Inc., Trillium Therapeutics Inc., Virtuoso BINco, Inc., and others.

• Promising Relapsing Refractory Multiple Myeloma Pipeline Therapies include Elranatamab, Venetoclax, Daratumumab, Carfilzomib, Pomalidomide, Bortezomib, LBH589 (panobinostat), ATG-010, and others.

Discover how the Relapsing Refractory Multiple Myeloma treatment paradigm is evolving. Access DelveInsight's in-depth Pipeline Analysis for a closer look at promising breakthroughs @ Relapsing Refractory Multiple Myeloma Clinical Trials and Studies

Relapsing Refractory Multiple Myeloma Overview

Multiple myeloma (MM) is a blood disorder marked by the proliferation of malignant, monoclonal plasma cells in the bone marrow (BM) and/or outside sites. Relapsed refractory multiple myeloma (RRMM) happens when the cancer returns or fails to respond to treatment after initial therapy. Refractory myeloma arises from changes in cancer cells. As cancer cells persist, multiply, and divide, they accumulate more gene mutations.

Relapsing Refractory Multiple Myeloma Emerging Drugs Profile

• Mezigdomide: Bristol-Myers Squibb

Cereblon E3 ligase modulators (CELMoD) represent a category of oral immunomodulatory treatments engineered to boost the immune system and directly eliminate cancer cells by degrading tumor-supporting proteins. Bristol Myers Squibb is exploring two innovative CELMoD compounds, mezigdomide and iberdomide, for multiple myeloma, designed to enhance the proven effectiveness of IMiD agents with better tolerability, simpler dosing, and potential to improve outcomes. These compounds leverage cereblon to degrade Ikaros and Aiolos proteins, halting tumor cell growth, triggering cell death, and stimulating immune responses. Mezigdomide achieves maximum degradation of Ikaros and Aiolos, increasing apoptosis in myeloma cells. From Phase I/II interim data, mezigdomide combined with weekly DEX (40 mg; 20 mg if >75 years) demonstrated encouraging results in a highly resistant patient group. Mezigdomide is under Phase III investigation for Relapsed or Refractory Multiple Myeloma.

• Iopofosine: Cellectar Biosciences, Inc.

Iopofosine is a small-molecule Phospholipid Drug Conjugate designed to deliver iodine-131 (a radioisotope) precisely to cancer cells, minimizing harm to healthy ones. This feature sets it apart from many conventional treatments. Iopofosine is being tested in the CLOVER-WaM Phase 2 pivotal trial for relapsed/refractory (r/r) Waldenstrom's macroglobulinemia (WM), a Phase 2b trial in r/r multiple myeloma (MM) patients, and the CLOVER-2 Phase 1 trial for various pediatric cancers. The U.S. Food and Drug Administration awarded iopofosine Fast Track Designation for WM patients with two or more prior treatments, as well as r/r MM and r/r diffuse large B-cell lymphoma (DLBCL). Orphan Drug Designations (ODDs) were granted for WM, MM, neuroblastoma, rhabdomyosarcoma, Ewing's sarcoma, and osteosarcoma. Iopofosine also received Rare Pediatric Disease Designation (RPDD) for neuroblastoma, rhabdomyosarcoma, Ewing's sarcoma, and osteosarcoma. The European Commission issued ODDs for r/r MM and WM.

• ORIC-533: ORIC Pharmaceuticals

ORIC-533, an orally available small molecule inhibitor of CD73, a crucial element in the adenosine pathway thought to contribute to resistance against chemotherapy- and immunotherapy-based regimens, is being developed for multiple myeloma. The drug is currently in Phase I clinical trials for Relapsed or Refractory Multiple Myeloma.

The Relapsing Refractory Multiple Myeloma Pipeline report provides insights into

• The report furnishes comprehensive details on organizations advancing therapies for Relapsing Refractory Multiple Myeloma, including the total treatments each company is developing.

• It examines various therapeutic candidates categorized into initial, intermediate, and advanced development stages for Relapsing Refractory Multiple Myeloma management.

• Relapsing Refractory Multiple Myeloma Companies are engaged in precision therapeutics with ongoing and paused (inactive or halted) initiatives.

• Relapsing Refractory Multiple Myeloma Drugs in progress, sorted by development phase, delivery route, target receptor, standalone or combined therapy, unique action mechanisms, and molecular category.

• Comprehensive review of partnerships (corporate alliances and academic ties), licensing deals, and funding information to drive future growth in the Relapsing Refractory Multiple Myeloma market.

Get a detailed analysis of the latest innovations in the Relapsing Refractory Multiple Myeloma pipeline. Explore DelveInsight's expert-driven report today! @ Relapsing Refractory Multiple Myeloma Unmet Needs

Relapsing Refractory Multiple Myeloma Companies

Bristol-Myers Squibb, I-MAB Biopharma, Pfizer, Arcellx, Gilead Sciences, Novartis, Array Biopharma, Hrain Biotechnology Co., Ltd., Cartesian Therapeutics, Xencor, Takeda, Sorrento Therapeutics, Heidelberg Pharma AG, Ichnos Sciences, Allogene Therapeutics, Harpoon Therapeutics, Cellectis, Poseida Therapeutics, Regeneron Pharmaceuticals, ONK Therapeutics, TeneoOne, iTeos Therapeutics, Oricell Therapeutics, Anaveon AG, Luminary Therapeutics, Seagen Inc., Trillium Therapeutics Inc., Virtuoso BINco, Inc., and others.

Relapsing Refractory Multiple Myeloma pipeline report assesses the therapeutic potential of pipeline drugs by Route of Administration. Products are grouped under different ROAs, including

• Intra-articular

• Intraocular

• Intrathecal

• Intravenous

• Ophthalmic

• Oral

• Parenteral

• Subcutaneous

• Topical

• Transdermal

Relapsing Refractory Multiple Myeloma Products have been categorized under various Molecule types such as

• Oligonucleotide

• Peptide

• Small molecule

Obtain DelveInsight's latest report to gain strategic insights into upcoming Relapsing Refractory Multiple Myeloma Therapies and key Developments @ Relapsing Refractory Multiple Myeloma Market Drivers and Barriers, and Future Perspectives

Scope of the Relapsing Refractory Multiple Myeloma Pipeline Report

• Coverage- Global

• Relapsing Refractory Multiple Myeloma Companies- Bristol-Myers Squibb, I-MAB Biopharma, Pfizer, Arcellx, Gilead Sciences, Novartis, Array Biopharma, Hrain Biotechnology Co., Ltd., Cartesian Therapeutics, Xencor, Takeda, Sorrento Therapeutics, Heidelberg Pharma AG, Ichnos Sciences, Allogene Therapeutics, Harpoon Therapeutics, Cellectis, Poseida Therapeutics, Regeneron Pharmaceuticals, ONK Therapeutics, TeneoOne, iTeos Therapeutics, Oricell Therapeutics, Anaveon AG, Luminary Therapeutics, Seagen Inc., Trillium Therapeutics Inc., Virtuoso BINco, Inc., and others.

• Relapsing Refractory Multiple Myeloma Pipeline Therapies- Elranatamab, Venetoclax, Daratumumab, Carfilzomib, Pomalidomide, Bortezomib, LBH589 (panobinostat), ATG-010, and others.

• Relapsing Refractory Multiple Myeloma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination

• Relapsing Refractory Multiple Myeloma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Which companies are leading the race in Relapsing Refractory Multiple Myeloma drug development? Find out in DelveInsight's exclusive Pipeline Report-access it now! @ Relapsing Refractory Multiple Myeloma Emerging Drugs and Major Companies

Table of Contents

• Introduction

• Executive Summary

• Relapsing Refractory Multiple Myeloma: Overview

• Pipeline Therapeutics

• Therapeutic Assessment

• Relapsing Refractory Multiple Myeloma- DelveInsight's Analytical Perspective

• Late Stage Products (Phase III)

• Mezigdomide: Bristol-Myers Squibb

• Mid Stage Products (Phase II)

• Iopofosine: Cellectar Biosciences, Inc.

• Early Stage Products (Phase I)

• ORIC-533: ORIC Pharmaceuticals

• Preclinical and Discovery Stage Products

• Drug Name: Company Name

• Inactive Products

• Relapsing Refractory Multiple Myeloma Key Companies

• Relapsing Refractory Multiple Myeloma Key Products

• Relapsing Refractory Multiple Myeloma- Unmet Needs

• Relapsing Refractory Multiple Myeloma- Market Drivers and Barriers

• Relapsing Refractory Multiple Myeloma- Future Perspectives and Conclusion

• Relapsing Refractory Multiple Myeloma Analyst Views

• Relapsing Refractory Multiple Myeloma Key Companies

• Appendix

About Us

DelveInsight is a premier market research and consulting firm specializing in healthcare, delivering top-tier intelligence and analysis to guide strategic decisions. Our expert team, with profound knowledge of life sciences and healthcare, provides tailored research services and insights worldwide. Reach out for reliable, precise, and timely data to maintain a competitive edge.

Contact Us

Kanishk

kkumar@delveinsight.com